SLC1A2 and Parkinson disease: Salvatore et al. use a novel GLAST inhibitor UCPH-101 ((2-amino-5,6,7,8-tetrahydro-4-(4-methoxyphenyl)-7-naphthalen-1-yl)-5-oxo-4H-chromene-3-carbonitrile) and GLT-1 inhibitor DHK to evaluate the role of GLAST and GLT-1 in PD.